These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 18604237)
1. The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys. Haushalter TM; Friedrichs GS; Reynolds DL; Barecki-Roach M; Pastino G; Hayes R; Bass AS Br J Pharmacol; 2008 Aug; 154(7):1457-64. PubMed ID: 18604237 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. Ollerstam A; Visser SA; Persson AH; Eklund G; Nilsson LB; Forsberg T; Wiklund SJ; Gabrielsson J; Duker G; Al-Saffar A J Pharmacol Toxicol Methods; 2006; 53(2):174-83. PubMed ID: 16140023 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. Ollerstam A; Visser SA; Duker G; Forsberg T; Persson AH; Nilsson LB; Björkman JA; Gabrielsson J; Al-Saffar A J Pharmacol Toxicol Methods; 2007; 56(2):131-44. PubMed ID: 17689270 [TBL] [Abstract][Full Text] [Related]
4. A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog. Ollerstam A; Persson AH; Visser SA; Fredriksson JM; Forsberg T; Nilsson LB; Eklund G; Wiklund SJ; Gabrielsson J; Duker G; Al-Saffar A J Pharmacol Toxicol Methods; 2007; 55(1):35-48. PubMed ID: 16581270 [TBL] [Abstract][Full Text] [Related]
5. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. Parkinson J; Visser SA; Jarvis P; Pollard C; Valentin JP; Yates JW; Ewart L J Pharmacol Toxicol Methods; 2013; 68(3):357-66. PubMed ID: 23567074 [TBL] [Abstract][Full Text] [Related]
6. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes. Lengyel C; Varró A; Tábori K; Papp JG; Baczkó I Br J Pharmacol; 2007 Aug; 151(7):941-51. PubMed ID: 17533421 [TBL] [Abstract][Full Text] [Related]
7. Dynamic analysis of dofetilide-induced changes in ventricular repolarization. Lande G; Maison-Blanche P; Fayn J; Ghadanfar M; Coumel P; Funck-Brentano C Clin Pharmacol Ther; 1998 Sep; 64(3):312-21. PubMed ID: 9757155 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. Watson KJ; Gorczyca WP; Umland J; Zhang Y; Chen X; Sun SZ; Fermini B; Holbrook M; Van Der Graaf PH J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854 [TBL] [Abstract][Full Text] [Related]
9. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. Chaves AA; Zingaro GJ; Yordy MA; Bustard KA; O'Sullivan S; Galijatovic-Idrizbegovic A; Schuck H; Christian DB; Hoe CM; Briscoe RJ J Pharmacol Toxicol Methods; 2007; 56(2):103-14. PubMed ID: 17643323 [TBL] [Abstract][Full Text] [Related]
10. Calculation of QT shift in non clinical safety pharmacology studies. Champeroux P; Martel E; Fowler JS; Maurin A; Sola ML; Jude S; Elamrani F; Weyn AA; Laveissiere A; Lala P; Richard S J Pharmacol Toxicol Methods; 2009; 59(2):73-85. PubMed ID: 19135537 [TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988 [TBL] [Abstract][Full Text] [Related]
12. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin. Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307 [TBL] [Abstract][Full Text] [Related]
13. Confounders and Pharmacological Characterization When Using the QT, JTp, and Tpe Intervals in Beagle Dogs. Boulay E; Troncy E; Accardi MV; Pugsley MK; Downey AM; Miraucourt L; Huang H; Menard A; Tan W; Dubuc-Mageau M; Sanfacon A; Guerrier M; Authier S Int J Toxicol; 2020; 39(6):530-541. PubMed ID: 33063577 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval. Allen MJ; Oliver SD; Newgreen MW; Nichols DJ Br J Clin Pharmacol; 2002 Jan; 53(1):59-65. PubMed ID: 11849196 [TBL] [Abstract][Full Text] [Related]
15. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. Lu HR; Remeysen P; Somers K; Saels A; De Clerck F J Cardiovasc Electrophysiol; 2001 May; 12(5):538-45. PubMed ID: 11386514 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Le Coz F; Funck-Brentano C; Morell T; Ghadanfar MM; Jaillon P Clin Pharmacol Ther; 1995 May; 57(5):533-42. PubMed ID: 7768076 [TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Allen MJ; Nichols DJ; Oliver SD Br J Clin Pharmacol; 2000 Sep; 50(3):247-53. PubMed ID: 10971309 [TBL] [Abstract][Full Text] [Related]
18. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation. Liu G; Xue X; Gao C; Huang J; Qi D; Zhang Y; Dong JZ; Ma CS; Yan GX J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522677 [TBL] [Abstract][Full Text] [Related]
19. Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortium. Boulay E; Authier S; Bartko T; Greiter-Wilke A; Leishman D; Li D; Nichols JV; Pierson J; Rossman EI; Valentin JP; Vicente J; Walisser J; Troncy E; Wisialowski TA J Pharmacol Toxicol Methods; 2024; 129():107543. PubMed ID: 39019200 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. Tham TC; MacLennan BA; Burke MT; Harron DW J Cardiovasc Pharmacol; 1993 Mar; 21(3):507-12. PubMed ID: 7681516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]